PyrAmes
Founded 2016 · 14 employees on LinkedIn · 3 known investors
Find your way into PyrAmes
709 people in our graph share verified history with the PyrAmes team — schools, employers, funds. One of them is your warm intro.
PyrAmes develops a noninvasive, continuous wireless blood pressure monitoring platform (Boppli) for neonatal and pediatric patients, as well as adults, addressing the need for continuous BP monitoring without invasive arterial lines. The company operates in the digital health and medical device space.
Also known as PyrAmes Health
Founders & leadership
PyrAmes was founded in 2016 by Xina Quan.
Investors · 3
Company profile
researched Aug 2026PyrAmes (PyrAmes Health) is a digital health company developing continuous non-invasive blood pressure monitoring (cNIBP) technology intended to replace or supplement intermittent cuff measurements and invasive arterial lines. The company positions accurate blood pressure measurement as the starting point for clinical treatment decisions and is building wireless BP monitoring for patients across the age spectrum, from newborns to seniors.
The product portfolio comprises three platforms: Boppli, an accurate, non-invasive, continuous, wireless BP monitor for neonatal and pediatric patients; Bosimi, a cNIBP platform for adult inpatient and emergency care; and Bosimi@Home, aimed at diagnostics, treatment validation and home medical management. Boppli does not require calibration. The company frames the clinical need around figures it cites from third-party literature and public health sources: more than 50% of NICU admissions could benefit from BP monitoring but would not receive an arterial line due to invasiveness and cost; 50% of US adults are affected by high blood pressure; and raised blood pressure is associated with 7.6 million deaths worldwide annually.
Traction
Boppli received FDA 510(k) clearance in 2023 following submission of pivotal clinical study results, and the underlying technology received FDA Breakthrough Device Designation in 2020. The pivotal study was conducted at five hospitals in the U.S. and Canada and published in Neonatology in 2025. The company has also been recognized in competitions and programs including the American Heart Association Health Tech Competition (2023), the NIH RADx Tech Maternal Health Challenge (2023), and the SCCM Discovery Critical Care Innovation Incubator pitch event in 2026.
Latest developments
In March 2026, PyrAmes announced it won the SCCM Pitch Award at the Pitch-a-Palooza: Showcasing Innovations in Critical Care event at the 2026 Critical Care Congress of the Society of Critical Care Medicine in Chicago, receiving a $10,000 prize for a presentation titled "Creating a New Standard of Care for Blood Pressure Measurement" delivered by co-founder and CEO Xina Quan. In May 2025, the journal Neonatology published the Boppli pivotal clinical study.
▸Full profile — market position, technology, go-to-market, geography
Market position
PyrAmes competes against the current standards of care it references: intermittent oscillometric cuffs, which provide only spot measurements, and invasive arterial lines, which it describes as cumbersome and costly and often not used in neonatal patients who could benefit from continuous monitoring.
Technology
The core technology is a wireless, non-invasive sensor-based approach to continuous blood pressure measurement (cNIBP) that does not require calibration, applied in form factors suited to neonates, pediatric patients, adult inpatient and emergency care settings, and home use. The company's scientific basis is reflected in peer-reviewed work co-authored by its team, including a review of advances in non-invasive blood pressure monitoring published in Sensors (2021) and a pivotal clinical study of the Boppli monitor published in Neonatology, which compared Boppli readings against arterial lines at five hospitals in the United States and Canada and reported good accuracy and usability.
Go-to-market
Hospital and critical care providers treating neonatal and pediatric patients, including NICUs; adult inpatient and emergency care departments; and, via the Bosimi@Home platform, patients managing blood pressure outside the hospital.
Geography
Clinical validation work for Boppli was conducted at five hospitals in the United States and Canada; company references to hypertension prevalence and regulatory pathways center on the United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 6
launches, deals, and filingsPyrAmes won the SCCM Pitch Award at the Pitch-a-Palooza: Showcasing Innovations in Critical Care event at the 2026 Critical Care Congress hosted by the Society of Critical Care Medicine in Chicago, receiving a $10,000 prize for the presentation "Creating a New Standard of Care for Blood Pressure Measurement" by CEO Xina Quan.
$10K source ↗
The journal Neonatology published "Accuracy and Safety of a Continuous Noninvasive Blood Pressure Monitor in Neonates," describing PyrAmes' pivotal clinical study for Boppli conducted at five hospitals in the U.S. and Canada comparing Boppli readings with arterial lines.
The American Heart Association Center for Health Technology & Innovation selected PyrAmes as the best business pitch at its annual Health Tech Competition during Scientific Sessions 2023; PyrAmes was one of five finalists.
Results of the Boppli pivotal clinical study were submitted to the FDA, resulting in 510(k) clearance.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- PyrAmespyrameshealth.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does PyrAmes do?
- PyrAmes develops continuous, noninvasive wireless blood pressure monitoring platforms for neonatal, pediatric and adult patients.
- Who founded PyrAmes?
- PyrAmes was founded by Xina Quan in 2016.
- Who are PyrAmes's investors?
- PyrAmes's investors include Texas HALO Fund, Decent Capital, XTX Markets.